HNGE vs OMCL vs TDOC

For growth investors, Hinge Health, Inc.

(HNGE) is the stronger pick with 50. 6% revenue growth year-over-year, versus -1. 5% for Teladoc Health, Inc. (TDOC). Omnicell, Inc. (OMCL) offers the better valuation at 854. 0x trailing P/E (19. 5x forward), making it the more compelling value choice. Analysts rate Hinge Health, Inc. (HNGE) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Omnicell, Inc.

is actually cheaper at 19. 5x.

Over the past 5 years, Hinge Health, Inc.

(HNGE) delivered a total return of +74. 0%, compared to -95. 3% for Teladoc Health, Inc. (TDOC). Over 10 years, the gap is even starker: HNGE returned +74. 0% versus TDOC's -41. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Omnicell, Inc.

(OMCL) is the lower-risk stock at 1. 13β versus Teladoc Health, Inc. 's 1. 85β — meaning TDOC is approximately 64% more volatile than OMCL relative to the S&P 500. On balance sheet safety, Hinge Health, Inc. (HNGE) carries a lower debt/equity ratio of 2% versus 75% for Teladoc Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hinge Health, Inc.

(HNGE) is pulling ahead at 50. 6% versus -1. 5% for Teladoc Health, Inc. (TDOC). On earnings-per-share growth, the picture is similar: Teladoc Health, Inc. grew EPS 80. 6% year-over-year, compared to -33. 6% for Hinge Health, Inc.. Over a 3-year CAGR, TDOC leads at 1. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Omnicell, Inc.

(OMCL) is the more profitable company, earning 0. 2% net margin versus -89. 9% for Hinge Health, Inc. — meaning it keeps 0. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OMCL leads at 0. 4% versus -92. 9% for HNGE. At the gross margin level — before operating expenses — HNGE leads at 79. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Omnicell, Inc.

(OMCL) trades at 19. 5x forward P/E versus 26. 0x for Hinge Health, Inc. — 6. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OMCL: 51. 2% to $57. 20.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Omnicell, Inc.

(OMCL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 13)). Teladoc Health, Inc. (TDOC) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (OMCL: +12. 4%, TDOC: -41. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: HNGE is a small-cap high-growth stock; OMCL is a small-cap quality compounder stock; TDOC is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.